Dr. Michael J. Zelefsky, MD

Dr. Zelefsky practices at NYU Langone - Tisch Hospital in New York, New York.

Dr. Zelefsky's NPI, 1093785065, was assigned on January 24, 2006. Dr. Zelefsky graduated from Albert Einstein College of Medicine of Yeshiva University in 1986. Dr. Zelefsky holds New York license 171062.

Dr. Zelefsky's primary practice is NYU Langone - Tisch Hospital, at 550 1st Ave, New York, NY 10016 in New York County. The practice phone is (212) 263-1481.

Dr. Zelefsky's primary practice is NYU Langone - Tisch Hospital in New York, New York. Dr. Zelefsky is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Zelefsky to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zelefsky practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Zelefsky's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Zelefsky is licensed in New York.

CMS data shows 2,153 Medicare services from Dr. Zelefsky across 17 procedure codes in 2024, for 326 Medicare patients. Medicare paid $231,375 for them.

CMS counts 326 Medicare patients who saw Dr. Zelefsky in 2024. The largest group is 65 to 74, with 163 patients. 75% of them have cancer, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Zelefsky's median patient age at 73, with 1% women.

In 2024, Dr. Zelefsky wrote 20 Medicare Part D claims for 11 patients. 60% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $325 in total drug cost. In 2021, CMS named 23 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Zelefsky for performance year 2024, reported as part of a group. Dr. Zelefsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 93 papers to Dr. Zelefsky, published from 2014 to 2025. 2019 was the busiest year, with 17. The most frequent topics are Prostatic Neoplasms, Brachytherapy and Prostate-Specific Antigen. Dr. Zelefsky has published most often in Brachytherapy. Dr. Zelefsky's most frequent co-authors are Marisa A. Kollmeier, MD, Daniel J. Gorovets, MD and Sean Matthew McBride, MD.

CMS Open Payments shows 330 general payments to Dr. Zelefsky from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Boston Scientific Corporation paid the most, $622,597.

Dr. Zelefsky graduated from Albert Einstein College of Medicine of Yeshiva University in 1986.